Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents
Objective. To compare healthcare utilization (HCU) and costs of women newly diagnosed with metastatic breast cancer (mBC) by receipt of HER2-targeted agents (H2T) and among H2T subgroups. Methods. Adult women newly diagnosed with mBC (index date) during 2008–2012 were followed until enrollment end o...
Saved in:
| Main Authors: | Nicole Meyer, Yanni Hao, Xue Song, Nianwen Shi, William Johnson, Jaqueline Willemann Rogerio, Denise A. Yardley |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2014/475171 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
by: Pluard TJ, et al.
Published: (2025-03-01) -
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
by: Hope S. Rugo, et al.
Published: (2025-08-01) -
Efficiency of Healthcare Expenditure in the Pre-Pandemic and Pandemic Periods
by: Alina Vysochyna, et al.
Published: (2023-03-01) -
The Impacts of Breakthrough Drug Classes on Total Healthcare Expenditures
by: Zeynal Karaca, et al.
Published: (2016-02-01) -
Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy
by: Federico Sottotetti, et al.
Published: (2025-05-01)